FY2024 EPS Estimates for Stereotaxis Lowered by Roth Capital

Stereotaxis, Inc. (NYSEAMERICAN:STXS) – Stock analysts at Roth Capital decreased their FY2024 earnings estimates for shares of Stereotaxis in a research report issued to clients and investors on Tuesday, November 12th. Roth Capital analyst J. Wittes now anticipates that the company will earn ($0.24) per share for the year, down from their previous estimate of ($0.22). The consensus estimate for Stereotaxis’ current full-year earnings is ($0.25) per share. Roth Capital also issued estimates for Stereotaxis’ Q4 2024 earnings at ($0.04) EPS, Q1 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.17) EPS.

Stereotaxis Stock Performance

NYSEAMERICAN STXS opened at $2.09 on Friday. Stereotaxis has a twelve month low of $1.41 and a twelve month high of $3.29.

Stereotaxis (NYSEAMERICAN:STXS) last released its quarterly earnings results on Monday, November 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). The firm had revenue of $9.20 million for the quarter, compared to the consensus estimate of $6.80 million. Stereotaxis had a negative net margin of 85.79% and a negative return on equity of 153.10%.

Institutional Investors Weigh In On Stereotaxis

Several hedge funds and other institutional investors have recently modified their holdings of STXS. Virtu Financial LLC grew its position in Stereotaxis by 56.0% during the first quarter. Virtu Financial LLC now owns 32,690 shares of the company’s stock worth $85,000 after buying an additional 11,739 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Stereotaxis during the 1st quarter worth approximately $58,000. Bank of New York Mellon Corp grew its holdings in shares of Stereotaxis by 247.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 189,592 shares of the company’s stock worth $345,000 after purchasing an additional 135,041 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Stereotaxis by 7.7% during the first quarter. Vanguard Group Inc. now owns 2,613,966 shares of the company’s stock valued at $6,822,000 after purchasing an additional 187,437 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Stereotaxis by 46.2% in the second quarter. Renaissance Technologies LLC now owns 488,700 shares of the company’s stock valued at $889,000 after purchasing an additional 154,400 shares in the last quarter. Institutional investors and hedge funds own 45.35% of the company’s stock.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.